Patrick Yeramian, MD, Clinical Research Associate
Dr. Yeramian has
over 20 years of experience with the clinical development of innovative
formulations, new chemical entities and biotechnology derived drugs including
integrated development plans and Phase I-IV clinical trials. Dr. Yeramian holds
a Medical Degree from the University of Paris together with a Master of Clinical
Science in experimental oncology and a Graduate Degree in molecular virology.
He also earned a Master of Business Administration from Rutgers University.
Starting in 1987 he served in positions of increasing responsibilities in
companies in Europe and since 1992 in the US where he was a Director for
clinical research for hemato-oncology, infectious diseases and women health at
G.D. Searle-Monsanto (Pfizer group). In this later position he was instrumental
in the clinical development and registration in the US of new products and line
extensions in the women health and fertility franchise, including Flagyl SR� and
Synarel� (a GnRH agonist). Most recently he was Chief Medical Officer and Vice
President Medical Affairs for the Viragen group where he directed the clinical
development of Multiferon�, a new interferon drug, until its approval in Europe
for treatment of viral hepatitis and malignant melanoma. Since 2000, Dr.
Yeramian established an independent consulting practice and has provided support
and guidance to emergent companies in the US and Europe to develop their global
registration strategy and implement their US and international clinical plans.